Vanda Pharmaceuticals Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 32c
August 1, 2018 4:03 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.14, $0.32 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $47.35 million versus the consensus estimate of $47.28 million.
"We are excited with the year to date HETLIOZ sales performance, which demonstrates continued... More
